Astrocytomas are composed of heterogeneous cell populations. Compared to grade IV 41 glioblastoma, low-grade astrocytomas have more differentiated cells and are associated 42 with a better prognosis. Therefore, inducing cellular differentiation may serve as a 43 therapeutic strategy. The nuclear factor one (NFI) transcription factors are essential for 44 normal astrocytic differentiation and therefore could be effectors of cellular 45 differentiation in glioblastoma. We analysed expression of family members NFIA and 46 NFIB using high-grade astrocytoma mRNA expression datasets, and with 47 immunofluorescence co-staining. Their expression is reduced in glioblastomas and is 48 associated with differentiated and mature astrocyte-like cells at a cellular level. 49
Astrocytomas are characterised by high cellular heterogeneity, resulting in complex 59 combinations of proliferating and differentiated cells (Aum et al., 2014; Louis et al., 60 2007; Patel et al., 2014) . Compared with grade IV glioblastoma (GBM), lower grade 61 astrocytomas consist predominantly of well-differentiated cells, and are associated with 62 reduced aggressiveness and better prognosis (Louis et al., 2007) . Hence, increasing 63 cellular differentiation could render a tumour less aggressive and improve survival. 64
This argument supports the notion that differentiation therapy could serve as a feasible 65 therapeutic strategy. An example where this strategy has been remarkably successful is 66 the treatment of acute promyelocytic leukaemia (APML) using retinoic acid (RA) 67 (Huang et al., 1988) . This success is the result of a multitude of studies investigating 68 the role of RA in driving haematopoietic cell differentiation and targeting the fusion 69 protein PML-RARa (Nowak et al., 2009) . 70 71 Investigation of the response of GBM cell lines to inducers of differentiation did not 72 yield promising results, as the responses appear transient and vary between cell lines 73 (Campos et al., 2010; Caren et al., 2015; Choschzick et al., 2014) . This is unsurprisingly 74
given the endogenous function of these differentiation agents in normal brain cells. For 75 example, RA has different functions depending on cell state, and is able to promote or 76 inhibit differentiation at different stages of astrogliogenesis (Faigle et al., 2008) . It is 77 also ineffective in driving neuronal progenitor cell differentiation (Hadinger et al., 78 2009 ). One approach to overcoming such challenges is to target the endogenous 79 mechanisms that are directly involved in producing mature, differentiated glial cells 80 and re-deploy them in astrocytomas. 81 82 A promising candidate that may regulate differentiation in astrocytomas is the nuclear 83 factor one (NFI) family of transcription factors. These proteins are essential for normal 84 glial differentiation (Gobius et al., 2016; Namihira et al., 2009; Piper et al., 2010; Piper 85 et al., 2009; Shu et al., 2003) . During development, NFI are expressed in progenitor 86 cells that give rise to various differentiated cell populations in the dorsal telencephalon 87 (Bunt et al., 2017; Plachez et al., 2008) . Their expression drives the differentiation of 88 these cells (Gobius et al., 2016; Namihira et al., 2009; Piper et al., 2010) , with NFIA 89 and NFIB expression persisting in mature astrocytes (Chen et al., 2017a) . In Nfia and 90
Nfib knockout embryos, the generation of mature astrocytes is reduced, and progenitor 91 cells remain in a proliferative state for a prolonged period (Piper et al., 2009; Shu et al., 92 2003) . Overexpression of these genes is also sufficient to rapidly convert induced 93 pluripotent stem cells into functional astrocytes in vitro (Caiazzo et al., 2015; Canals et 94 al., 2018; Tchieu et al., 2019) . These findings reflect the essential role of NFIA and 95 NFIB as regulators of astrocytic differentiation. 96 97 In astrocytomas, higher expression levels of NFI correlate with lower grade tumours 98 that are composed of more differentiated cells (Song et al., 2010; Stringer et al., 2016) . 99
Loss of heterozygosity (LOH) of NFIB as a consequence of chromosome 9p loss is a 100 common occurrence in the tumour progression and is present in 40% of all GBM (Brat 101 et al., 2004; Rasheed et al., 2002) . The down-regulation of NFI expression may be a 102 108 The induction of NFIA or NFIB in GBM cell lines in vitro induces the expression of 109 astrocyte differentiation markers such as GFAP and FABP7 (Brun et al., 2009; Glasgow 110 et al., 2014; Gobius et al., 2016; Stringer et al., 2016) , indicating that overexpression 111 of NFI might be sufficient to drive astrocytic differentiation. NFIA and NFIB function 112 very similarly to drive glial differentiation in the developing brain (Gobius et al., 2016; 113 Namihira et al., 2009; Piper et al., 2010) . We demonstrated recently that NFIB 114 overexpression in vitro reduced in GBM cell proliferation and inhibited growth when 115 xenografted into mice (Stringer et al., 2016) , although whether NFIA plays a similar 116 role is unknown. Here, we investigate whether NFIA and NFIB drive astrocytic 117 differentiation in astrocytomas in vivo. Using expression datasets and 118 immunofluorescence co-staining, we demonstrate that the endogenous expression of 119 NFIA and NFIB positively correlate with each other, and that their expression in 120 astrocytomas is associated with the expression of differentiated cell markers. 121
Furthermore, by manipulating their expression in patient-derived GBM xenografts in 122 vivo, we reveal that induced expression of either NFI is sufficient to promote tumour 123 cell differentiation. These findings suggest that the NFI-pathway is a promising 124 therapeutic target to induce differentiation in astrocytomas. 125
126

Results
127
NFIA and NFIB expression is decreased in grade IV GBM
128
To compare the expression of NFIA and NFIB, and their relationship in different grades 129 of astrocytomas, we analysed seven large mRNA expression datasets of human 130 astrocytoma samples. Both NFIA and NFIB expression were reduced in GBM as 131 compared to grade I-III astrocytomas (Fig. 1a) , demonstrating that the expression of 132 both NFIA and NFIB is higher in tumours with more differentiated tumours, and lower 133 in poorly differentiated tumours. We also observed a positive correlation between NFIA 134 and NFIB expression in GBM samples across ten datasets ( Fig. 1b ; Supplementary 135 Table 2 ). Although the strength of the correlation coefficient varied among datasets, 136 this variability may be explained by LOH of NFIB observed in a subset of GBM 137 samples (Brat et al., 2004; Rasheed et al., 2002) . Separating tumour samples based on 138 NFIB copy number significantly improved the correlation coefficient between NFIA 139 and NFIB expression in samples where these data were available (Fig. 1c ). The 140 trendlines representing the NFIB-diploid and haploinsufficient tumour samples had a 141 similar correlation coefficient and were separated by approximately one 2 log unit. This 142 meant that when comparing between samples with similar NFIA expression, NFIB 143 expression was halved in NFIB-haploinsufficient samples, as would be expected when 144 one NFIB allele is lost. Similar analyses for NFIA haploinsufficiency, which is rarely 145 observed in GBM, resulted in only a small improvement in the correlation coefficient 146 ( Supplementary Table 3 ). 147 148 NFIA and NFIB are co-expressed at the cellular level in GBM tumours
149
The correlation between NFIA and NFIB expression in tumour samples does not 150 necessarily mean that these genes are co-expressed within the same cells. We 151 investigated this by first examining NFIA and NFIB expression in GBM tumours 152 analysed by single cell RNA-seq (Patel et al., 2014; Venteicher et al., 2017) . 153
Similar to our observations with whole tumour samples, we observed that the 154 expression of NFIA and NFIB positively correlated with each other at the single-cell 155 level ( Fig. 1d and e; Supplementary Table 4 ). To validate this at the protein level, we 156 then performed immunofluorescence co-staining of NFIA and NFIB in patient-derived 157 GBM xenografts ( Supplementary Table 1a and 5). Quantification was performed with 158 two biological replicates in two non-necrotic 500 x 500 µm ROIs per tumour. In the 159 QBI-01 xenograft, which represents a tumour with fewer NFI-positive cells in general, 160 half of all NFIA-positive cells co-stained for NFIB, whereas over a third of the NFIB-161 positive cells were also NFIA-positive ( Fig. 1f and g) . The co-expression of NFIA and 162 NFIB was observed in more cells for the QBI-02 xenograft, in which at least 80% of 163 cells expressed both NFIA and NFIB. We therefore conclude that NFIA and NFIB show 164 a high degree of co-expression within the same cells in GBM tumours. 165 166 NFIA and NFIB expression correlates with astrocytic differentiation genes 167 in GBM cells 168 GBM tumours consist of a heterogenous mix of cell types (Aum et al., 2014; Patel et 169 al., 2014 ) . Highly aggressive tumours that consist predominantly of proliferating cells 170 still harbour differentiated tumour cells that are not proliferating (Louis et al., 2007) . 171
Given their role as regulators of cell differentiation during development, we 172 hypothesized that NFIA and NFIB are associated with genes that correspond with a 173 differentiated cell state. To investigate this, we performed gene ontology (GO) analyses 174 on gene sets that were independently derived from each of the three largest GBM 175 mRNA expression datasets ( Supplementary Table 6 and 7). We generated four gene 176 sets for each mRNA expression dataset, with each set consisting of 500 genes. The first 177 two sets consisted of the top genes that positively correlated with NFIA or NFIB, 178 respectively, while the remaining two sets consisted of the top genes that showed 179 negative correlation with NFIA or NFIB. Each set was then subjected to GO analyses 180 to identify which GO Biological Process terms were enriched. 181
182
The six gene sets that were positively correlated with NFIA or NFIB (two sets for each 183 of the mRNA expression datasets) returned a combined total of 345 unique GO terms 184 (p<0.001) ( Fig. 2a ; Supplementary Table 7 ). 114 of these terms (33%) occurred in at 185 least four of the six positively correlated gene sets, but were completely absent from 186 the six gene sets that are negatively correlated with NFIA or NFIB. These included GO 187 terms associated with transcription, metabolic processes and development. 14 of these 188 terms were shared between all six positively correlated gene sets. These are likely to 189 represent genes that are co-expressed in NFIA+ and NFIB+ cells, and are enriched for 190 terms representative of neurodevelopment and cell differentiation processes ( Fig. 2b) . 191
Overall, these findings are in line with the strong co-expression of NFIA and NFIB 192 observed in these datasets ( Fig. 1b-g) , and indicative of their overlapping function in 193 regulating differentiation. Notably, no GO terms associated with proliferation were 194 enriched in any of the positively or negatively correlated gene sets, suggesting that NFI 195 expression is indicative of tumour differentiation state and not proliferative potential. 196
197
We next performed similar analyses using the two largest single-cell mRNA-seq 198 datasets derived from individual GBM tumours. Other single-cell datasets were 199 excluded, as these did not contain sufficient cells for reliable correlation analyses. The 200 four gene sets representing NFI positively correlated genes were enriched for a 201 combined total of 220 GO terms (p < 0.00005). 70 of these terms (32%) were shared at 202 least once between the NFIA and NFIB gene sets, but were completely absent from the 203 gene sets representing negatively correlated genes ( Fig. 2c ; Supplementary Table 8 and 204 9). Similar to our analyses of whole GBM tumours, the 38 GO terms shared between 205 all four positively correlated gene sets represented neurodevelopmental processes, such 206 as neurogenesis, gliogenesis, and cell differentiation ( Supplementary Table 9 ). These 207 findings also held true for gene expression datasets of two GBM cell lines collected 208 from different passages and culture conditions ( Supplementary Table 10 and 11) (Lee 209 et al., 2006) , further supporting the premise that NFI expression is a marker of 210 differentiated cells. 211
212
To determine whether the correlated gene sets were associated with specific cell types, 213
we compared these sets with gene expression signatures that represent mature astrocyte, 214 oligodendrocyte or neuron-specific genes as reported by three independent groups 215 ( Supplementary Table 12 ) (Cahoy et al., 2008; Lein et al., 2007; McKenzie et al., 2018) . 216
The NFIA and NFIB positively correlated gene sets were associated with astrocytic 217 genes ( Fig. 2d) . In contrast, genes that negatively correlated with NFIA or NFIB were 218 enriched for oligodendrocytic markers. This suggests that NFI-expressing tumour cells 219 are likely to resemble mature astrocytes rather than oligodendrocytes or neurons. To determine whether NFI expression is associated with astrocytic markers in GBM 224 tumours in vivo, we performed immunofluorescence co-staining on sections derived 225 from five primary GBM samples, five xenografts derived from GBM cell lines and 226 three patient-derived xenograft tumours ( Fig. 3 ; Supplementary Fig. 1 and 2) (Stringer 227 et al., 2019) . All samples expressed both NFIA and NFIB, and displayed co-staining of 228 markers of astrocytic differentiation. Cell counts demonstrated that the majority of 229 NFIA-or NFIB-positive cells (~80%) were also positive for GFAP or S100B ( Fig. 4 ; 230 Supplementary Table 13 and 14). In contrast, only one third of the NFIA-or NFIB-231 positive cells co-stained with the proliferation marker Ki67. Hence, NFI expression is 232 associated with the expression of mature astrocytic markers. 233
234
To further delineate whether NFI-expressing cells are fully differentiated, we analysed 235 the combined co-staining of GFAP and Ki67 ( Fig. 3 and 4 ; Supplementary Fig. 1 and 236 2; Supplementary Table 13 and 14) . No difference in the co-staining pattern was 237 observed between NFIA-positive or NFIB-positive cells. Over half of the NFI-positive 238 cells co-expressed only GFAP ( Fig. 4c ), indicative of fully differentiated cells, whereas 239 less than a third of these cells were both GFAP-and Ki67-positive. The identity of the 240 latter cells is questionable, but could perhaps represent cells that have just begun 241 differentiating. We also observed that a subset of GFAP-positive cells was devoid of 242 NFIA or NFIB expression. However, we were unable to determine whether both NFIA 243 and NFIB were concurrently absent in these cells, as our NFIA and NFIB antibodies 244 were derived from the same host species. 245 246 Expression of NFIA or NFIB induces tumour cell differentiation 247 NFI expression is indicative of differentiated cells that express mature astrocytic 248 markers in GBM, but whether these transcription factors can actually drive the 249 differentiation of proliferating cancer cells remains unclear. Overexpression of either 250 NFIA or NFIB is sufficient to induce the expression of astrocytic markers in vitro (Brun 251 et al., 2009; Canals et al., 2018; Stringer et al., 2016) , but this remains to be 252 demonstrated for tumours in vivo. In addition, no study has yet to compare both NFIA 253 and NFIB under similar conditions. To investigate whether NFI expression can drive 254 astrocytic differentiation in vivo, we introduced NFIA or NFIB overexpression 255 plasmids via in vivo electroporation into subcutaneous xenografts. As a proof of 256 concept, we electroporated xenografts of the U251 GBM cell line, which is responsive 257 to NFIB induction in vitro (Brun et al., 2009) . Electroporated xenografts were sectioned 258 and co-labelled for GFAP, Ki67 and green fluorescent protein (GFP), which is 259 indicative of cells that were successfully electroporated (Fig. 5a ). The overall number 260 of GFAP-positive cells increased in NFIB-electroporated xenografts as compared to 261 xenografts electroporated with the control plasmid ( Fig. 5b ; Supplementary Table 15 ). 262
Specifically, we observed a concurrent decrease in GFAP-negative, Ki67-positive cells 263 and a subsequent increase in GFAP-positive, Ki67-negative cells, indicating that 264 proliferative cells transitioned into a differentiated state upon NFIB overexpression. A 265 small but insignificant increase in the number of GFAP-positive, Ki67-positive cells 266 was observed, suggesting that these could represent proliferative cells that are 267 transitioning to a differentiated state. 268
269
To determine whether overexpression of NFIA or NFIB exerts the same effect, we 270 electroporated NFIA, NFIB or control plasmids into xenografts representing two 271 patient-derived xenograft lines ( Fig. 5c and e; Supplementary Table 15 ). These lines 272 responded similarly to either NFIA or NFIB overexpression, with the number of GFAP-273 positive, Ki67-negative cells increasing to approximately 80% in NFIA-or NFIB-274 electroporated xenografts ( Fig. 5d and f ). We observed a concurrent reduction in the 275 number of cells that were GFAP-negative, Ki67-positive, and GFAP-negative, Ki67-276 negative, while GFAP-positive, Ki67-positive cells increased. Immuno-labelling of the 277 QBI-02 xenografts with S100B, another marker expressed in mature astrocytes, 278 returned similar findings ( Fig. 5g ; Supplementary Fig. 4a and b ). Thus, we conclude 279 that either NFIA or NFIB is sufficient to induce astrocytic differentiation in GBM. 280 281
Discussion
282
In this study, we have demonstrated that both NFIA and NFIB function as regulators 283 of astrocytic differentiation in astrocytoma. NFI expression is higher in lower grade 284 astrocytomas, and the expression of NFIA and NFIB in GBM is typically associated 285 with genes representing the mature astrocytic state. Furthermore, both these 286 transcription factors are co-expressed in GBM cells that also express mature astrocytic 287 markers. Most importantly, in vivo overexpression of either NFIA or NFIB in 288 xenografts is sufficient to drive proliferative cells towards astrocytic differentiation. 289
Hence, NFIA and NFIB retain their developmental role as inducers of astrocytic 290 differentiation in astrocytoma, and could therefore act as tumour suppressors within a 291 therapeutic context. 292
293
Although strong evidence exists to suggest that NFIB acts as a tumour suppressor in 294 astrocytoma (Johansson et al., 2004; Patel et al., 2014; Stringer et al., 2016; Vyazunova 295 et al., 2014) , the role of NFIA remains disputable (Glasgow et al., 2013; Johansson et 296 al., 2004; Lee et al., 2014; Patel et al., 2014; Song et al., 2010; Vyazunova et al., 2014) . 297
In vitro experiments suggest that NFIA promotes rather than suppresses cancer cell 298 proliferation (Lee et al., 2014) . However, our findings demonstrate that both NFIA and 299 NFIB function as tumour suppressors as they drive proliferating cells to differentiate 300 towards an astrocytic fate in vivo. Whether they share similar functions in other tumours 301 requires further study, but this is unlikely to be the case. These transcription factors are 302 widely expressed in many tissues during development, and both oncogenic and tumour 303 suppressive roles have been reported which may be tissue-specific (Chen et al., 2017b) . 304
For instance, NFIA plays a vital role in the development of oligodendrocytes (Kang et 305 al., 2012; Wong et al., 2007) , with the expression of NFIA, but not NFIB, being retained 306 in adult oligodendrocytes (Chen et al., 2017a) . In line with this, oligodendrogliomas 307 tend to demonstrate lower NFIA expression than astrocytomas, in contrast to NFIB 308 (Song et al., 2010) . This lower expression may be associated with the partial loss of 309 chromosome 1p31, which is more often observed in oligodendrogliomas than in 310 astrocytomas (Houillier et al., 2010) . Interestingly, overexpression of NFIA in a mouse 311 model of oligodendroglioma resulted in tumours resembling astrocytomas (Glasgow et 312 al., 2014) . In spite of this, as this study did not investigate whether these cells remained 313 proliferative, another possible interpretation of the findings is that NFIA 314 overexpression caused the cells to differentiate towards the astrocytic lineage, similar 315 to our observations. 316 317 NFI proteins have also been implicated as tumour suppressors in other brain cancers, 318 such as the SHH-subtype of medulloblastomas (Genovesi et al., 2013; Wu et al., 2012) . 319
This role was strongly corroborated using a mouse model of SHH-subtype 320 medulloblastoma with heterozygous deletion of Nfia (Genovesi et al., 2013) . Compared 321 to normal Nfia expression, loss of one allele increased tumour incidence and decreased 322 tumour latency. Hence, NFI may broadly function as inducers of differentiation in 323 different brain tumour cell types. 324
325
The identification of the Nfi loci as common insertion sites in insertional mutagenesis 326 mouse models demonstrates that reduced Nfi expression contributes to glioma 327 tumorigenesis (Johansson et al., 2004; Vyazunova et al., 2014) . However, how tumour 328 cells suppress NFI expression in astrocytomas in vivo to evade differentiation remains 329 unclear. As mutations of the NFI genes are rare, haploinsufficiency of NFIA or NFIB 330 appears to be the most common pathway through which their expression is reduced. It 331 is also likely that NFI expression is regulated on a transcriptional level in proliferating 332 tumour cells that have evaded differentiation commitment. Unfortunately, little is 333 known about the upstream regulators of NFI during normal astrogliogenesis or in 334 astrocytoma, so this requires further investigation. However, due to the strong positive 335 correlation between NFIA and NFIB expression, it is likely that both have similar 336 upstream regulators. A recent study proposed that NFIA expression could be mediated 337 by TGFb in normal gliogenesis (Tchieu et al., 2019) . Whether reduced NFIA expression 338 in GBM is due to ectopic TGFb signalling remains to be elucidated. Aside from this, 339 post-transcriptional regulation may also contribute to NFI down-regulation. For 340 example, the expression of the microRNAs miR-124 and miR-129 positively correlates 341 with increased glioma grade, but inversely correlates with NFIB expression (Ho et al., 342 2013; Silber et al., 2008) . Indeed in vitro experiments have demonstrated that 343 microRNAs regulate NFI expression in astrocytoma cell lines, but their significance in 344 vivo remains to be determined. Greater emphasis on understanding how NFI is 345 suppressed in tumour cells is required for effective therapeutic manipulation of the NFI-346 mediated differentiation pathway. 347
348
In addition to direct manipulation of the NFI pathway as a potential differentiation 349 therapy, increased expression of NFI may also act as a biomarker indicative of 350 differentiation when testing novel therapeutic agents or for diagnostic purposes. It is 351 not known whether NFI expression was induced and sustained for the differentiation 352 agents tested (Campos et al., 2010; Caren et al., 2015; Choschzick et al., 2014) . The 353 abundance of NFI proteins could even indicate whether a tumour would be more prone 354 to induction of differentiation for differentiation therapies instead of, or in combination 355 with, the current standard treatment regime. Nevertheless, any diagnostic or prognostic 356 value of NFIA or NFIB to clinical management will require further investigation. 357
358
In conclusion, our study demonstrates that both NFIA and NFIB play a direct role in 359 inducing tumour differentiation in astrocytoma. Given that tumours with fewer 360 differentiated cells are associated with a poorer clinical outcome, a deeper 361 understanding of the NFI-mediated differentiation mechanisms may reveal a potential 362 therapeutic strategy to reduce the proliferative potential of GBM cells via 363 differentiation, and thereby improve patient survival. 364 365
Material and Methods
367
In silico analyses
368
To assess gene expression in human glioma samples, public expression datasets 369 GSE50161 (Griesinger et al., 2013) , GSE36245 (Sturm et al., 2012) , GSE16011 370 (Gravendeel et al., 2009 ), GSE7696 (Murat et al., 2008) , GSE43378 (Kawaguchi et al., 371 2013) , GSE53733 (Reifenberger et al., 2014) , GSE57872 (Patel et al., 2014) , 372 GSE108474 (Gusev et al., 2018) , GSE118793, GSE4290 (Sun et al., 2006) , GSE89567 373 (Venteicher et al., 2017) , and TCGA (Brennan et al., 2013) were analysed and 374 visualised using the R2: microarray analysis and visualization platform 375 (http://r2.amc.nl) as previously described (Bunt et al., 2010) . Gene set enrichment 376 analyses were performed using The Database for Annotation, Visualization and 377
Integrated Discovery (DAVID) 6.8 online tool (Huang da et al., 2009a (Huang da et al., , 2009b . The establishment of xenografts was performed as previously described with minor 390 modifications (Carlson et al., 2011) . For patient-derived GBM xenografts (QBI-01, 391 QBI-02, and QBI-03), fresh GBM patient tumour samples were obtained from the 392
Wesley Medical Research BioBank with approval from the University of Queensland 393
Human Ethics Committee. Upon receipt, samples were disaggregated using a scalpel 394 blade and mixed with extracellular matrix (ECM) gel (Sigma-Aldrich, St. Louis, 395 Missouri) in a 1:1 ratio on ice. Cell line-derived xenografts were generated from U251 396 (Ponten et al., 1968 ) and patient-derived GBM cell lines BAH1, SJH1, RKI1, and WK1 397 obtained from the QIMR Berghofer Medical Research Institute (Day et al., 2013; 398 Stringer et al., 2019) . The U251 GBM cell line was maintained in vitro in Dulbecco's 399
Modified Eagle Medium supplemented with 10% (v/v) foetal bovine serum (FBS) (Life 400
Technologies, Carlsbad, California), whereas patient-derived cell lines were cultured 401 as adherent monolayers in ECM gel-coated vessels using RHB-A stem cell culture 402 medium (Life Technologies) supplemented with 20 ng/mL epidermal growth factor 403 (Life Technologies), 10 ng/mL fibroblast growth factor 2 (Life Technologies), and 404
StemPRO NSC SFM (Life Technologies) as previously described (Pollard et al., 2009). 405 All cell lines were incubated at 37ºC with 5% CO 2 . To dissociate adherent cells, 1 mL 406 of 0.25% pre-warmed trypsin (Life Technologies) was added to the T25 culture flask 407 (Corning) for U251, whereas 1 mL pre-warmed StemPro® Accutase® (Life NFI expression in established GBM xenografts was driven using the piggyBac system 418 as described previously (Chen et al., 2012) . pPBCAGIG, pPBCAGIG-NFIB or 419 pPBCAGIG-NFIA donor plasmids were co-electroporated with pCAG-PBase as a 420 helper plasmid into established xenografts of 0.1-0.2 cm 3 (Hsieh et al., 2003; 421 Tsurushima et al., 2008) . pPBCAGIG was generated by cloning the CAG-ires-eGFP 422 cassette from pCAGIG into pPBCAG-eGFP. Subsequently, HA-tagged Nfia or HA-423 tagged Nfib (Piper et al., 2014; Stringer et al., 2016) Pennsylvania) and rehydrated through a series of ethanol (100% and 70%) washes. 455
Antigen retrieval was performed using an antigen decloaking chamber (Biocare 456 Medical, Pacheco, California). Mounted sections were heated to 125ºC for 4 minutes 457 at 15 psi in 10 mM sodium citrate buffer (pH 6.0) with 0.05% (v/v) Tween 20. 458
Following antigen retrieval, sections were washed with PBS prior to 459 immunohistochemistry. All tissues used are listed in Supplementary Table 1a . 460 461 Immunohistochemistry
462
Fluorescence immunohistochemistry was performed as previously described with 463 minor modifications (Plachez et al., 2008) . After antigen retrieval, sections were 464 incubated for 2 h in blocking solution containing 10% (v/v) normal donkey or goat 465 serum (Jackson Laboratories, Bar Harbor, Maine), 0.9% (v/v) hydrogen peroxide 466 (Chem-Supply, Gillman, Australia) and 0.2% (v/v) Triton X-100 (Sigma-Aldrich) in 467 PBS. Sections were then incubated overnight with primary antibodies diluted in 2% 468
(v/v) serum and 0.2% (v/v) Triton X-100 in PBS. The primary antibodies used are listed 469
in Supplementary Table 1b . Sections were washed in PBS for 3x20 minutes before 470 incubating with secondary antibody. Linear regression was used to determine the correlation of two genes in expression 514 datasets, using the R2: microarray analysis and visualization platform (http://r2.amc.nl) 515 as previously described (Bunt et al., 2010) . The differential expression of NFI between 516 tumour types was compared with a Welch's t-test on normalised data. To compare the 517 co-staining distribution of NFIA or NFIB with other cell markers between GBM tissues 518 or to determine gene enrichment, a paired one-way ANOVA with Bonferroni's multiple 519 comparison correction was performed. To compare the co-staining of GFP-positive 520 electroporated cells with markers in GBM xenografts between different plasmids, a 521
Welch's t-test was performed. These tests were computed with GraphPad Prism 7 522 (GraphPad Software, San Diego, California). 523
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